Literature DB >> 11678715

Catalytic asymmetric allylic C-H activation as a surrogate of the asymmetric Claisen rearrangement.

H M Davies1, P Ren, Q Jin.   

Abstract

[reaction: see text]. Tetrakis[N-[4-dodecylphenyl)sulfonyl]-(S)-prolinato]-dirhodium [Rh2(S-DOSP)4] catalyzed decomposition of methyl aryldiazoacetates in the presence of alkenes results in allylic C-H activation by means of a rhodium-carbene induced C-H insertion. The resulting gamma,delta-unsaturated esters are equivalent to products that would be traditionally obtained from an asymmetric Claisen rearrangement. Highly regio- and enantioselective C-H insertions can be achieved, and in certain cases, good diastereocontrol is also possible.

Entities:  

Year:  2001        PMID: 11678715     DOI: 10.1021/ol0167255

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  5 in total

1.  Combined C-H functionalization/Cope rearrangement with vinyl ethers as a surrogate for the vinylogous Mukaiyama aldol reaction.

Authors:  Yajing Lian; Huw M L Davies
Journal:  J Am Chem Soc       Date:  2011-07-18       Impact factor: 15.419

Review 2.  Catalytic C-H functionalization by metal carbenoid and nitrenoid insertion.

Authors:  Huw M L Davies; James R Manning
Journal:  Nature       Date:  2008-01-24       Impact factor: 49.962

3.  Catalytic Asymmetric Intermolecular Allylic Functionalization of Unactivated Internal Alkenes.

Authors:  Liela Bayeh; Uttam K Tambar
Journal:  ACS Catal       Date:  2017-10-27       Impact factor: 13.084

4.  Catalytic asymmetric reactions for organic synthesis: the combined C-H activation/Cope rearrangement.

Authors:  Huw M L Davies; Qihui Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

5.  Finding Opportunities from Surprises and Failures. Development of Rhodium-Stabilized Donor/Acceptor Carbenes and Their Application to Catalyst-Controlled C-H Functionalization.

Authors:  Huw M L Davies
Journal:  J Org Chem       Date:  2019-10-10       Impact factor: 4.354

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.